Overview

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Status:
Recruiting
Trial end date:
2023-06-16
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533, LYS006 and MAS825 in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006 and MAS825 have an adequate clinical profile for further clinical development.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal